Savara (SVRA)
(Delayed Data from NSDQ)
$3.96 USD
-0.06 (-1.49%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $3.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
Savara Inc. [SVRA]
Reports for Purchase
Showing records 21 - 40 ( 48 total )
Company: Savara Inc.
Industry: Medical - Drugs
Disappointing IMPALA Topline Data Challenges Advancement in aPAP Patients, PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
We are dropping coverage of SVRA shares due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: Savara Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Savara Inc.
Industry: Medical - Drugs
Company: Savara Inc.
Industry: Medical - Drugs
Insights From the Japanese Respiratory Society Meeting; Anticipation for IMPALA and AVAIL Data; Reit Buy and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Continue to Find Clinical Risk Profile of Assets Attractive: Reit Buy and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Savara Inc.
Industry: Medical - Drugs
Company: Savara Inc.
Industry: Medical - Drugs
Company: Savara Inc.
Industry: Medical - Drugs
Renewed Investor Focus on Non-NTM Programs Is Healthy for the Stock; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Continued Progress as We Eagerly Await Clinical Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Biomedical and Genetics
Company: Savara Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Savara Inc.
Industry: Medical - Biomedical and Genetics
Company: Savara Inc.
Industry: Medical - Biomedical and Genetics
We Continue to Be Supportive of Molgradex in PAP; Reit Buy and $22 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Biomedical and Genetics
Upside Justified by Predictability of Pipeline Success; Initiating With Buy and $22PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Biomedical and Genetics
We are placing shares of SVRA Under Review, and transferring coverage to Jotin Marango, M.D., Ph.D.
Provider: Roth Capital Partners, Inc.
Company: Savara Inc.
Industry: Medical - Biomedical and Genetics
Company: Savara Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Savara Inc.
Industry: Medical - Biomedical and Genetics
Progress on Multiple Fronts and Data- Filled 2018
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M